I. Smith

发表

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

M. Dowsett, R. Gelber, J. Baselga, 2005, The New England journal of medicine.

Intratumoral Estrogen Disposition in Breast Cancer

P. Lønning, M. Dowsett, J. Geisler, 2010, Clinical Cancer Research.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer.

J. Yarnold, I. Smith, H. Ford, 1985, Cancer treatment reports.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

M. Dowsett, S. Chandarlapaty, I. Smith, 2015, Science Translational Medicine.

Triple-negative breast cancer.

Jorge S Reis-Filho, W. Foulkes, J. Reis-Filho, 2010, The New England journal of medicine.

Mitoxantrone (novantrone): a review of experimental and early clinical studies.

I. Smith, Ian E. Smith, 1983, Cancer treatment reviews.

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Jingqin Luo, Mitch Dowsett, Matthew J. Ellis, 2008, Journal of the National Cancer Institute.

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

I. Smith, Z. Siddik, D. Newell, 2004, Cancer Chemotherapy and Pharmacology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

J. Cuzick, A. Tutt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

R. Gray, T. Powles, C. Wilson, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies

I. Smith, I. E. Smith, 2001, Anti-cancer drugs.

Navelbine and the anthrapyrazoles.

I. Smith, A. Jones, 1994, Hematology/oncology clinics of North America.

Adjuvant treatment in breast cancer

T. Powles, W. Allum, I. Smith, 1992, The Lancet.

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Alan Mackay, Alan Ashworth, Mitch Dowsett, 2006, Breast Cancer Research.

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.

B. Gusterson, S. Ebbs, S. Johnston, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

David Cameron, Richard Bell, Mitch Dowsett, 2007, The Lancet.

Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.

I. Smith, T. Kordbacheh, W. Law, 2016, Breast.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Patrick Neven, István Láng, A. Giobbie-Hurder, 2011, The Lancet. Oncology.

The Extended Adjuvant Treatment Strategy in Early Breast Cancer

I. Smith, 2006 .

Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.

I. Smith, 2004, Breast.

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

M. Dowsett, S. Johnston, I. Smith, 2019, JAMA oncology.

Vinorelbine – a clinical review

I. Smith, R. Gregory, 2000, British Journal of Cancer.

Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.

I. Smith, M. Parton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

M. Dowsett, J. Salter, Z. Ghazoui, 2013, Clinical Cancer Research.

Clinical Commentary

Jacqueline A Palace, I. Smith, A. Leary, 2010, Multiple Sclerosis.

Mechanisms of resistance to aromatase inhibitors

M. Dowsett, S. Johnston, I. Smith, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

T. Powles, J. Kanis, L. Ottestad, 2006, Breast Cancer Research.

Aromatase inhibitors in early breast cancer therapy.

I. Smith, 2004, Seminars in oncology.

Challenges in the endocrine management of breast cancer.

H. Mouridsen, I. Smith, C. Rose, 2003, Breast.

Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.

I. Smith, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice.

V. Courtenay, I. Smith, J. Mills, 1978, Cancer research.

Expression of estrogen responsive genes in breast cancers correlates with plasma estradiol levels in postmenopausal women.

M. Ellis, M. Dowsett, Z. Ghazoui, 2009 .

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

L. Assersohn, K. Last, D. Tait, 2006, British Journal of Cancer.

Hodgkin's Disease in Children

I. Smith, J. Gazet, T. Mcelwain, 1977, British Journal of Cancer.

Management of Hodgkin's disease in childhood.

I. Smith, T. Mcelwain, 1977, Archives of disease in childhood.

Serum p53 antibodies: predictors of survival in small-cell lung cancer?

T. Soussi, I. Smith, M. O'Brien, 2000, British Journal of Cancer.

Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes.

I. Smith, G. Walsh, S. O'neill, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Management of breast cancer in older and frail patients.

I. Smith, C. Fribbens, 2015, Breast.

Endocrine therapy for advanced/metastatic breast cancer.

I. Smith, G. Schiavon, 2013, Hematology/oncology clinics of North America.

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

M. Dowsett, L. Zabaglo, I. Smith, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.

R. Laing, T. Hickish, S. Ebbs, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Who would have thought a single Ki67 measurement would predict long-term outcome?

M. Dowsett, J. Salter, L. Zabaglo, 2009, Breast Cancer Research.

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)

M. Dowsett, A. Urruticoechea, I. Smith, 2008, Breast Cancer Research and Treatment.

Medical treatment of early breast cancer. II: endocrine therapy

I. Smith, S. Chua, 2006, BMJ : British Medical Journal.

Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.

P. Ellis, I. Smith, A. Ring, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer

L. Assersohn, S. Johnston, A. Urruticoechea, 2005, British Journal of Cancer.

A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

A. Howell, T. Powles, M. Dowsett, 2004, Cancer Chemotherapy and Pharmacology.

Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.

I. Smith, B. Evans, R. Clutterbuck, 1984, British Journal of Cancer.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

M. Dowsett, S. Ebbs, J. Salter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Christopher A. Miller, E. Mardis, M. Dowsett, 2016, Nature Communications.

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

G. Hortobagyi, L. Carey, D. Yee, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JM8 Development and Clinical Projects

I. Smith, S. Harland, A. Calvert, 1984 .

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

E. Winer, J. Cuzick, A. Tutt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

N. Rahman, M. Dowsett, P. Ellis, 2015 .

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

D. Amadori, M. Dowsett, M. Gnant, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-up tests to detect recurrent disease: patient's reassurance or medical need?

I. Smith, G. Schiavon, 2013, Breast.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

A. Goldhirsch, M. Regan, A. Coates, 2011, Breast Cancer Research and Treatment.

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

R. Gelber, J. Baselga, B. Leyland-Jones, 2009 .

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009 .

Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions.

I. Smith, 2009, Breast.

S41 Targeting HER2 in the adjuvant setting: Dealing with new standards and open questions

I. Smith, 2009 .

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial

T. Powles, M. Dowsett, I. Smith, 2017, Cancer Prevention Research.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

T. Powles, M. Dowsett, I. Smith, 2007, Journal of the National Cancer Institute.

Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.

M. Sporn, K. Maclennan, M. Dowsett, 1992, Cancer research.

Pathogenesis of bone metastases in breast cancer

M. Dowsett, I. Smith, T. Iveson, 1993 .

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

G. Hortobagyi, L. Carey, D. Yee, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience

S. Johnston, I. Smith, N. Turner, 2021, British Journal of Cancer.

Cancer Therapy: Clinical Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011 .

Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration.

I. Smith, J. Stebbing, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

B. Xu, X. Pivot, J. Pierga, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Patient preference for extended palliative chemotherapy for non-small cell lung cancer

T. Hickish, M. Nicolson, I. Smith, 1995, The Lancet.

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study

J. Pierga, I. Smith, C. Thomssen, 2012, Oncology.

A. Buzdar, D. Finkelstein, P. Goss, 2015, European journal of cancer.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

W. Gradishar, A. Buzdar, D. Finkelstein, 2013, The Lancet. Oncology.

Survival from breast cancer in England and Wales up to 2001

I. Smith, A. Leary, 2008, British Journal of Cancer.

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment

M. Dowsett, M. Cheang, J. Robertson, 2019, JCO precision oncology.

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

C. Swanton, T. Yau, S. Johnston, 2006, Acta oncologica.

High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma

J. Yarnold, I. Smith, H. Ford, 2004, Cancer Chemotherapy and Pharmacology.

Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study

H. Mouridsen, I. Smith, J. Smyth, 2004, Investigational New Drugs.

Mitoxantrone: An active new agent in the treatment of advanced breast cancer

N. Pavlidis, I. Smith, R. Stuart-Harris, 2004, Cancer Chemotherapy and Pharmacology.

Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer.

N. Pavlidis, I. Smith, R. Stuart-Harris, 1983, Cancer treatment reviews.

Occult primary breast carcinoma presenting as axillary lymphadenopathy.

I. Smith, R. A’Hern, G. Walsh, 2002, Breast.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer.

M. Dowsett, J. Salter, I. Smith, 2010 .

New drugs for breast cancer

I. Smith, 2002, The Lancet.

Chemotherapy for elderly patients with lung cancer

T. Hickish, I. Smith, G. Middleton, 1995, The Lancet.

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

M. Dowsett, I. Smith, R. A’Hern, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Time Trends in the Outcome of Elderly Patients with Breast Cancer

S. Johnston, I. Smith, Y. Yap, 2008, The breast journal.

High incidence of HER-2 positivity in inflammatory breast cancer.

M. Dowsett, I. Smith, M. Hills, 2004, Breast.

The viability of marrow stored at 4oC

I. Smith, J. Millar, 1984 .

High-dose cyclophosphamide (7 g/m2) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer.

I. Smith, B. Evans, S. Harland, 1983, Cancer treatment reviews.

Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial

C. Normand, I. Smith, J. Haviland, 2002, BMJ : British Medical Journal.

Difficult Decisions Whether or not to give adjuvant chemotherapy for breast cancer

I. Smith, 2008 .

Whether or not to give adjuvant chemotherapy for breast cancer.

I. Smith, 1988, Postgraduate medical journal.

Controversies in the medical management of breast cancer.

I. Smith, 1985, Postgraduate medical journal.

Adjuvant chemotherapy for early breast cancer

I. Smith, 1983, British medical journal.

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.

A. Harris, I. Smith, J. Gazet, 1981, British medical journal.

A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.

D. Tait, I. Smith, G. Schiavon, 2013, Clinical breast cancer.

Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy

I. Smith, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer

I. Smith, M. Arnedos, S. Ashley, 2008, Breast Cancer Research and Treatment.

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease

M. Dowsett, M. Cheang, I. Smith, 2016, Clinical Cancer Research.

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

I. Smith, A. Ring, R. Jones, 2006, British Journal of Cancer.

Circulating tumour cells in breast cancer.

M. Dowsett, I. Smith, A. Ring, 2004, The Lancet. Oncology.

Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up

M. Dowsett, R. Gelber, J. Baselga, 2012 .

Studies of apoptosis in breast cancer

M. Dowsett, I. Smith, M. Parton, 2001, BMJ : British Medical Journal.

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

A. Howell, M. Dowsett, P. Ellis, 1997, International journal of cancer.

The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer.

M. Williams, I. Judson, I. Smith, 1990, British Journal of Cancer.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy

M. Dowsett, M. Clemons, I. Smith, 2017, npj Breast Cancer.

Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

H. Mouridsen, A. V. van Oosterom, I. Smith, 1984, European journal of cancer & clinical oncology.

Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? Treatment decision-making in advanced disease.

I. Smith, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Goals of Treatment for Patients With Metastatic Breast Cancer.

I. Smith, 2006, Seminars in oncology.

CARDIOTOXICITY ASSOCIATED WITH - MITOXANTRONE

I. Smith, R. Stuart-Harris, E. Olsen, 1984, The Lancet.

Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo

M. Dowsett, J. Salter, M. Baum, 1993 .

Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer.

I. Smith, J. Teale, I. Smith, 1988, British Journal of Cancer.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

A. Gown, S. Leung, T. Nielsen, 2022, Modern Pathology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV post-exposure prophylaxis: a case report

I. Smith, M. Forster, Rowan E Miller, 2009, Journal of Medical Case Reports.

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.

H. Groen, I. Smith, D. Uges, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1994, European journal of cancer.

Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

T. Powles, J. Kanis, L. Ottestad, 2006, Breast Cancer Research.

Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.

V. Miller, I. Smith, M. Slevin, 1998, American journal of clinical oncology.

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M. Dowsett, M. Cheang, D. Rea, 2022, EBioMedicine.

Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.

M. Gore, I. Smith, S. Sriskandan, 1994, Postgraduate medical journal.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors determining outcome after third line chemotherapy for metastatic breast cancer.

S. Johnston, U. Banerji, I. Smith, 2007, Breast.

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.

D. Talbot, I. Smith, A. Jones, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aromatase inhibitors: a dose-response effect?

I. Smith, 1999, Endocrine-related cancer.

LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER

M. Dowsett, I. Smith, J. Gazet, 1984, The Lancet.

Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.

A. Harris, I. Smith, J. Gazet, 1982, Cancer research.

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

M. Dowsett, M. Cheang, E. Mallon, 2022, Breast cancer research : BCR.

Metastatic orchioblastoma: alpha1-fetoprotein in diagnosis and combination chemotherapy in treatment: a case report.

I. Smith, T. Mcelwain, H. Eckstein, 1977, British journal of urology.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98

A. Coates, B. Thürlimann, L. Mauriac, 2007 .

Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.

J. Yarnold, I. Smith, H. Ford, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E. Perez, M. Piccart, H. Gómez, 2016, Journal of the National Cancer Institute.

UK guidance document: treatment of metastatic breast cancer.

D. Miles, I. Smith, I. Kunkler, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

J. Pierga, I. Smith, C. Thomssen, 2011, Breast Cancer Research and Treatment.

Inflammatory breast cancer—The Royal Marsden Hospital experience

S. Johnston, I. Smith, G. Walsh, 2010, Cancer.

Mesenteric desmoid tumours in Gardner's syndrome--review of medical treatments.

I. Smith, P. Zentler-Munro, B. Eagel, 1989, Postgraduate medical journal.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

N. Robert, D. Miles, I. Smith, 2010, Breast Cancer Research and Treatment.

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

T. Hickish, S. Johnston, I. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.

P. Lønning, M. Dowsett, D. Hayes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy.

J. Yarnold, P. Hoskin, I. Smith, 1986, Cancer treatment reports.

Multimodality therapy in inflammatory breast cancer: is there a place for surgery?

S. Ebbs, S. Johnston, I. Smith, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

D. Miles, I. Smith, A. Calvert, 2001, European journal of cancer.

Small cell lung cancer cell line from histologically and immunocytochemically negative bone marrow.

I. Smith, V. Macaulay, J. Millar, 1990, European journal of cancer.

New treatments for small cell lung cancer. When to test.

I. Smith, 1989, Chest.

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

J. Wanders, P. Schőffski, C. Sessa, 1994, European journal of cancer.

Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): an evaluation of lung toxicity.

J. Yarnold, I. Smith, G. Cherryman, 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Development and responses of brain metastases during treatment with trastuzumab emtansine (T‐DM1) for HER2 positive advanced breast cancer: A single institution experience

S. Johnston, I. Smith, N. Somaiah, 2018, The breast journal.

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

M. Dowsett, I. Smith, S. Banerjee, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

H. Gundacker, M. Dowsett, D. Miles, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.

M. Dowsett, I. Smith, D. Smithers, 1993, The Journal of clinical endocrinology and metabolism.

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

D. Hedley, I. Smith, M. Gordon, 1979, British Journal of Cancer.

5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391

P. Kellokumpu-Lehtinen, J. Pierga, I. Smith, 2009 .

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients

A. Howell, M. Dowsett, D. Evans, 2012, Breast Cancer Research and Treatment.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

M. Dowsett, J. Salter, I. Smith, 2010, Breast Cancer Research.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial

M. Dowsett, I. Smith, 2003 .

A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.

T. Powles, D. Easton, R. Coombes, 1986, Breast cancer research and treatment.

An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.

T. Powles, M. Dowsett, R. Coombes, 1992, European journal of cancer.

Aminoglutethimide in the treatment of advanced breast cancer.

I. Smith, R. Stuart-Harris, Ian E. Smith, 1984, Cancer treatment reviews.

Neoadjuvant Endocrine Therapy

I. Smith, 2004 .

Exon S Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor / pS 2 Status in Human Breast Cancer '

I. Smith, Nicholas, Dowsett, 2022 .

Immunohistochemical Phenotype after 20-Year Follow-Up of the Royal Marsden Tamoxifen Breast Cancer Prevention Trial (RMTBCPT).

M. Dowsett, I. Smith, S. Ashley, 2009 .

AUTOLOGOUS BONE MARROW RESCUE IS UNNECESSARY AFTER VERY-HIGH-DOSE CYCLOPHOSPHAMIDE

I. Smith, B. Evans, J. Millar, 1983, The Lancet.

Overview of gemcitabine activity in advanced breast cancer.

I. Smith, 2006, Seminars in oncology.

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

M. Dowsett, J. Parker, M. Cheang, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).

I. Smith, M. O'Brien, R. Gregory, 2001, Clinics in oncology.

PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMA

I. Smith, H. Ford, M. Jarman, 1980, The Lancet.

Premarin in the management of metastatic breast carcinoma in post-menopausal patients.

T. Powles, I. Smith, J. Gazet, 1979, Clinics in oncology.

Chemotherapy of human breast-carcinoma xenografts.

I. Smith, G. Steel, J. Gazet, 1980, British Journal of Cancer.

Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer.

P. Ellis, D. Talbot, I. Smith, 1995, European journal of cancer.

Predictors of response to aromatase inhibitors

M. Dowsett, I. Smith, S. Bulun, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

M. Dowsett, S. Ebbs, J. Salter, 2006, Clinical Cancer Research.

101. Change in expression of epidermal growth factor receptor and c-erb-B2 during the development of tamoxifen resistance in human breast cancer

M. Dowsett, S. Johnston, I. Smith, 1995 .

Palliative chemotherapy for advanced non-small cell lung cancer

I. Smith, 1994, British medical journal.

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.

A. Graeff, M. Leach, I. Smith, 1991, British Journal of Cancer.

Continuous infusional chemotherapy for early breast cancer: the Royal Marsden Hospital experience.

I. Smith, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug?

I. Smith, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary medical (neoadjuvant) chemotherapy for operable breast cancer: Building on early promise

K. Maclennan, M. Dowsett, M. Baum, 1992 .

Fadrozole and letrozole in advanced breast cancer: Clinical and biochemical effects

I. Smith, A. Norton, 2004, Breast Cancer Research and Treatment.

Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)

R. Gelber, J. Baselga, Bing-he Xu, 2013 .

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2014, Breast.

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.

T. Powles, A. Harris, M. Mitchell, 1983, British Journal of Cancer.

Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

W. Allum, I. Smith, A. Ring, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma.

J. Shuster, I. Smith, M. Wharam, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum insulin-like growth factor-I levels in patients with small cell lung cancer.

I. Smith, V. Macaulay, J. Teale, 1988, European journal of cancer & clinical oncology.

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth.

J. Miller, I. Smith, V. Macaulay, 1992, British Journal of Cancer.

CNS relapse despite prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC).

J. Yarnold, P. Hoskin, I. Smith, 1986, International journal of radiation oncology, biology, physics.

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Growth of human tumour cell colonies from biopsies using two soft-agar techniques.

V. Courtenay, I. Smith, P. Selby, 1978, British Journal of Cancer.

Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.

S. Cawthorn, M. Kissin, I. Smith, 1996, Journal of the National Cancer Institute.

Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial

D. Amadori, M. Dowsett, M. Gnant, 2016 .

Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule.

D. Talbot, I. Smith, M. O'Brien, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

M. Dowsett, S. Ebbs, J. Blohmer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-term presurgical treatment for all?

M. Dowsett, J. Salter, I. Smith, 2007, Breast Cancer Research.

Pre-operative endocrine therapy: focus on the clinical and biological results of the IMPACT trial

I. Smith, R. Jones, 2006 .

Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.

T. Powles, S. Ebbs, H. Bonnefoi, 1996, British Journal of Cancer.

A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma

C. Ryan, I. Smith, M. O'Brien, 2000, British Journal of Cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2005, The New England journal of medicine.

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

I. Smith, 2009, Breast Cancer Research.

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

Sung-Bae Kim, M. Piccart, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?

S. Johnston, U. Banerji, I. Smith, 2007, Breast.

Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience

I. Smith, A. Ring, N. Battisti, 2019, Breast Cancer Research and Treatment.

Enhancing endocrine response with novel targeted therapies

M. Dowsett, S. Johnston, I. Smith, 2008, Cancer.

Intercalated radio-chemotherapy in small cell lung cancer: toxicity and implications for future regimens.

J. Yarnold, P. Hoskin, I. Smith, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.

I. Judson, D. Talbot, I. Smith, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies.

M. Dowsett, A. Barrett, I. Smith, 1986, British Journal of Cancer.

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

N. Bogdanova, J. Pierga, I. Smith, 2008 .

MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.

T. Powles, I. Smith, 1993, Oncology.

UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.

D. Miles, S. Johnston, I. Smith, 2000, Oncology.

A high molecular weight non-bombesin/gastrin releasing peptide growth factor in small cell lung cancer.

I. Smith, V. Macaulay, J. Millar, 1987, British Journal of Cancer.

Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung

I. Smith, J. Smyth, H. Ford, 2004, Cancer Chemotherapy and Pharmacology.

Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.

D. Easton, R. Coombes, J. Yarnold, 1987, Cancer research.

AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA

T. Powles, I. Smith, A. Neville, 1978, The Lancet.

CVM versus ACE in the treatment of small cell lung cancer.

I. Smith, A. Jones, S. Ashley, 1993, Oncology.

Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

D. Talbot, I. Smith, D. Talbot, 1992, British Journal of Cancer.

Short term tamoxifen induces the cytoplasmic expression of c-erbB2 and BCL-2 in er-positive human primary breast cancer

K. Maclennan, M. Dowsett, J. Salter, 1992 .

First-line chemotherapy rechallenge after relapse in small cell lung cancer

I. Smith, M. Vincent, B. Evans, 2004, Cancer Chemotherapy and Pharmacology.

Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer.

M. Dowsett, I. Smith, I. Kozarewa, 2014 .

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

I. Smith, A. Calvert, S. Harland, 2004, Cancer Chemotherapy and Pharmacology.

A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma.

T. Powles, R. Coombes, D. Hedley, 1980, Cancer treatment reviews.

Prevention of doxorubicin-induced alopecia by scalp hypothermia: relation to degree of cooling

I. Smith, 1982 .

Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.

I. Smith, S. Kaye, B. Cantwell, 1988, European journal of cancer & clinical oncology.

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group

M. Ellis, S. Leung, T. Nielsen, 2020, Journal of the National Cancer Institute.

Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.

M. Dowsett, J. Reed, S. Krajewski, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proliferation marker Ki-67 in early breast cancer.

Mitch Dowsett, M. Dowsett, A. Urruticoechea, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.

M. Dowsett, I. Smith, D. Smithers, 1993, Cancer research.

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2009, Breast Cancer Research and Treatment.

Aromatase inhibitors in breast cancer.

Mitch Dowsett, M. Dowsett, I. Smith, 2003, The New England journal of medicine.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Richard Bell, Mitch Dowsett, 2017, The Lancet.

Tryptophan in the treatment of carcinoid crisis

A. Harris, I. Smith, 2004, Cancer Chemotherapy and Pharmacology.

Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors.

T. Powles, D. Hedley, I. Smith, 1978, Cancer treatment reports.

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

S. Ebbs, I. Smith, R. A’Hern, 1993, British Journal of Cancer.

High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.

I. Smith, C. Gallagher, F. Cairnduff, 1987, European journal of cancer & clinical oncology.

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011, Clinical Cancer Research.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Jorge S. Reis-Filho, Rosalind J. Cutts, Mitch Dowsett, 2015, Science Translational Medicine.

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition

M. Dowsett, I. Smith, E. López-Knowles, 2014, Breast Cancer Research.

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

A. Ashworth, M. Dowsett, J. Reis-Filho, 2010, Clinical Cancer Research.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Jack Cuzick, Lisa McShane, Christos Sotiriou, 2011, Journal of the National Cancer Institute.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Mitch Dowsett, Roger A'Hern, M. Dowsett, 2007, Journal of the National Cancer Institute.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

M. Dowsett, J. Mayordomo, J. Salter, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial

M. Dowsett, R. Gelber, J. Baselga, 2019, AntiCancer Research.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

M. Dowsett, G. Viale, I. Smith, 2013, Breast Cancer Research and Treatment.

Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

C. Perou, M. Ellis, M. Dowsett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCER

T. Powles, R. Coombes, I. Smith, 1980, The Lancet.

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

M. Dowsett, S. Ebbs, J. Salter, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

M. Dowsett, M. Cheang, E. Mallon, 2020, The Lancet. Oncology.

In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft

V. Courtenay, I. Smith, G. Steel, 1976, Nature.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

A. Giobbie-Hurder, R. Gelber, T. Ahern, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.

A. Barrett, I. Smith, S. Kaye, 1979, British Journal of Cancer.

Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom

A. Howell, R. Eeles, D. Easton, 2006, Clinical Cancer Research.

Chemosensitivity Studies on Human Tumour Cells from a Pancreatic Carcinoma Xenograft 1

I. Smith, 1979, Journal of the Royal Society of Medicine.

The effect of misonidazole on the radiation response of clonogenic human pancreatic carcinoma cells.

V. Courtenay, I. Smith, G. Steel, 1978, The British journal of cancer. Supplement.

A colony-forming assay for human tumour xenografts using agar in diffusion chambers.

V. Courtenay, I. Smith, M. Gordon, 1976, British Journal of Cancer.

Preventing late recurrence in hormone receptor-positive early breast cancer: a review.

I. Smith, N. Battisti, 2022, European journal of cancer.

Regression of carcinoid tumour with cyproheptadine.

A. Harris, I. Smith, 1982, British medical journal.

Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.

Robin L. Jones, I. Smith, 2006, The Lancet. Oncology.

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.

T. Powles, J. Nevalainen, J. Kanis, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells.

I. Smith, J. V. Van Wyk, V. Macaulay, 1990, Cancer research.

EPIC: an effective low toxicity regimen for relapsing lymphoma.

M. Gore, T. Hickish, D. Catovsky, 1993, British Journal of Cancer.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Anagha P. Jadhav, A. Gown, M. Ellis, 2022, Modern Pathology.

Platinum-based chemotherapy in triple-negative breast cancer.

S. Johnston, I. Smith, B. Sirohi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer

S. Lakhani, I. Smith, L. Fulford, 2004, British Journal of Cancer.

Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group.

G. Giaccone, O. Dalesio, H. Groen, 1997, European journal of cancer.

Adjuvant treatment in breast cancer

T. Powles, W. Allum, I. Smith, 1992, The Lancet.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

M. Dowsett, J. Parker, M. Cheang, 2016, Breast Cancer Research.

Status of adjuvant endocrine therapy for breast cancer

I. Smith, G. Schiavon, 2014, Breast Cancer Research.

Breast cancer and pregnancy.

P. Ellis, I. Smith, A. Ring, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2010, Journal of Clinical Pathology.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

C. Boshoff, M. Gore, S. Johnston, 2000, British Journal of Cancer.

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

R. Gelber, J. Baselga, T. Hickish, 2019, European journal of cancer.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

R. Gelber, M. Piccart, J. Baselga, 2018, Journal of the National Cancer Institute.

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

M. Dowsett, M. Cheang, E. Mallon, 2019, Breast Cancer Research.

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

Alan Ashworth, A. Ashworth, H. Gevensleben, 2013, Clinical Cancer Research.

Research needs in breast cancer

C. Hudis, K. Gelmon, G. Sledge, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer in adolescents and young women.

I. Smith, C. Shannon, 2003, European journal of cancer.

A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine.

I. Smith, A. Shorthouse, B. Evans, 1982, British Journal of Cancer.

Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?

S. Johnston, I. Smith, G. Walsh, 2011, Oncology.

Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

A. Ashworth, M. Dowsett, J. Reis-Filho, 2010 .

Advances in endocrine therapy and its implications for translational research

I. Smith, N. Turner, A. Sheri, 2009 .

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

T. Hickish, M. Nicolson, D. Talbot, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.

P. Ellis, M. Nicolson, D. Talbot, 1995, British Journal of Cancer.

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

P. Ellis, M. Nicolson, D. Talbot, 1995, British Journal of Cancer.

Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer.

I. Smith, D. Newell, J. Hardy, 1991, European journal of cancer.

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer.

I. Smith, J. Hardy, I. Smith, 1989, British Journal of Cancer.

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

T. Eisen, I. Smith, P. Ross, 2004, British Journal of Cancer.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2007, Breast Cancer Research and Treatment.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

A. Giobbie-Hurder, J. Forbes, P. Neven, 2013, Breast Cancer Research and Treatment.

Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2009, Breast Cancer Research and Treatment.

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Robin L. Jones, M. Dowsett, J. Reis-Filho, 2008, Breast Cancer Research and Treatment.

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

A. Ashworth, S. Lakhani, J. Reis-Filho, 2006, Journal of Clinical Pathology.

Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

I. Smith, D. Newell, K. Harrap, 1983, British Journal of Cancer.

Control of aromatase in breast cancer cells and its importance for tumor growth

A. Ashworth, M. Dowsett, I. Smith, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors

M. Dowsett, M. Cheang, L. Zabaglo, 2019, Clinical Cancer Research.

The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway.

A. Padhani, I. Smith, V. Varney, 2003, Lung cancer.

Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

A. Ashworth, C. Perou, N. Rahman, 2017 .

VP 16-213 in acute myelogenous leukaemia

I. Smith, T. Mcelwain, H. Clink, 1976, Postgraduate medical journal.

Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide.

M. H. Baker, I. Smith, J. Smyth, 1980, Cancer research.

Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.

E. Perez, J. Baselga, A. Wolff, 2013, The oncologist.

Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy

I. Smith, J. Mcvie, A. Oosterom, 2004, Cancer Chemotherapy and Pharmacology.

Mammography in the assessment of response to medical treatment of large primary breast cancer.

D. King, I. Smith, E. Moskovic, 1993, Clinical radiology.

A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy

I. Smith, Granisetron Study Group, 2005, Journal of Cancer Research and Clinical Oncology.

LHRH analogues in breast cancer: clever, but do we need them?

I. Smith, 1991, British Journal of Cancer.

ENCEPHALOPATHY WITH RAPID INFUSION IFOSFAMIDE/MESNA

I. Smith, R. Turner, T. J. Perren, 1987, The Lancet.

A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.

L. Assersohn, I. Smith, M. O'Brien, 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

Progression of endocrine therapies for breast cancer: where are we headed?

I. Smith, M. Arnedos, 2007, Expert review of anticancer therapy.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

I. Ellis, M. Dowsett, P. Ellis, 2009, The Lancet.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Designing adjuvant treatment based on biological measurements in the neoadjuvant setting

I. Smith, A. Kotsori, 2010, Breast Cancer Research.

Neoadjuvant/presurgical treatments

I. Smith, 2008, Breast Cancer Research.

Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer

M. Dowsett, P. Ellis, J. Salter, 2003, British Journal of Cancer.

Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients

J. Geisler, I. Smith, W. Miller, 2012, The Journal of Steroid Biochemistry and Molecular Biology.

Is there still a role for neoadjuvant therapy in breast cancer?

I. Smith, C. Shannon, 2003, Critical reviews in oncology/hematology.

Preoperative/neoadjuvant medical therapy for early breast cancer.

L. Lipton, I. Smith, 2001, The Lancet. Oncology.

Primary medical therapy for operable breast cancer.

J A McKinna, P A Trott, C. Fisher, 1989, European journal of cancer & clinical oncology.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Mitch Dowsett, Helen Anderson, Roger A'Hern, 2011, Journal of the National Cancer Institute. Monographs.

Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study

I. Smith, D. Jodrell, Duncan I. Jodrell, 2008, Cancer Chemotherapy and Pharmacology.

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

I. Smith, A. Kirby, G. Walsh, 2011, European journal of cancer.

Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.

A. Giobbie-Hurder, J. Forbes, R. Paridaens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

M. Dowsett, S. Johnston, I. Smith, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer

J. Forbes, R. Gelber, R. Paridaens, 2005 .

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.

J. Forbes, R. Gelber, R. Paridaens, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer.

A. Harris, I. Smith, J. Gazet, 1983, British medical journal.

Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.

T. Powles, A. Harris, I. Smith, 1982, Cancer research.

Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience

I. Smith, A. Ring, P. Osin, 2022, Breast Cancer Research and Treatment.

Aromatase inhibitors in early breast cancer treatment.

L. Mauriac, I. Smith, 2003, Seminars in oncology.

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

R. Gelber, J. Baselga, J. Mayordomo, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.

I. Smith, J. Reubi, V. Macaulay, 1991, British Journal of Cancer.

Does timing of adjuvant chemotherapy for early breast cancer influence survival?

I. Smith, S. Ashley, C. Shannon, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials.

N. Robert, D. Miles, I. Smith, 2009 .

Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC).

J. Pierga, I. Smith, C. Thomssen, 2009 .

Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer.

I. Smith, B. Evans, 1985, Cancer treatment reviews.

OP-JNCI200205 808..819

M. Ellis, S. Leung, T. Nielsen, 2021 .

A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.

T. Hickish, A. Norman, M. Nicolson, 1998, British Journal of Cancer.

Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.

C. Sotiriou, M. Dowsett, R. Gelber, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

J. Forbes, R. Gelber, R. Paridaens, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

M. Dowsett, S. Johnston, I. Smith, 2005, The Journal of Steroid Biochemistry and Molecular Biology.

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.

I. Smith, 1990, European Journal of Cancer.

Choosing treatment for metastatic breast cancer

A. Harris, I. Smith, R. Stuart-Harris, 1983, British medical journal.

Improving the therapeutic index of two alkylating agents.

I. Smith, R. Clutterbuck, J. Millar, 1980, British Journal of Cancer.

Signet-ring cell lymphoma of bone marrow.

K. Maclennan, D. Talbot, I. Smith, 1994, Journal of clinical pathology.

MULTIMODAL THERAPY FOR STAGE-II BREAST CANCER

T. Powles, I. Smith, 1978, The Lancet.

Mitoxantrone: A phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours

I. Smith, R. Stuart-Harris, 2004, Cancer Chemotherapy and Pharmacology.

New perspectives in lung cancer.5. New drugs in lung cancer.

D. Talbot, I. Smith, 1992, Thorax.

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.

M. Gore, I. Smith, Z. Siddik, 1987, European journal of cancer & clinical oncology.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

A. Giobbie-Hurder, J. Forbes, P. Neven, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).

H. Earl, I. Smith, P. Woll, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study.

T. Powles, I. Smith, E. Engelsman, 1980, European journal of cancer.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

István Láng, A. Giobbie-Hurder, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous bone marrow transplantation and solid tumors

O. Dalesio, I. Smith, J. Mcvie, 1984 .

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2015, Breast Cancer Research.

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

I. Smith, D. Jodrell, J. Mckinna, 1991, British Journal of Cancer.

Plastic mattresses and sudden infant death syndrome

I. Smith, P. Blair, C. Bacon, 1995, The Lancet.

Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques

M. Dowsett, L. Zabaglo, I. Smith, 2005, British Journal of Cancer.

Primary medical (neo-adjuvant) chemotherapy for operable breast cancer.

M. Baum, I. Smith, J. Mckinna, 1993, European journal of cancer.

A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.

P. Ellis, S. Johnston, I. Smith, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

I. Smith, A. Constantinidou, 2011, Breast.

Adjuvant treatment for early breast cancer.

I. Smith, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review

O. Dalesio, H. Groen, M. Parmar, 2007, The Lancet.

Sternal/para-sternal resection for parasternal local recurrence in breast cancer.

I. Smith, S. Ashley, G. Ladas, 2010, Breast.

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

I. Smith, B. Yeo, G. Walsh, 2015, Breast.

Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer

I. Smith, G. Gui, P. Osin, 2018, BJS open.

Maximizing clinical benefit with trastuzumab.

M. Untch, D. Cameron, I. Smith, 2004, Seminars in oncology.

Efficacy and safety of trastuzumab

Robin L. Jones, I. Smith, 2004, Expert opinion on drug safety.

High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.

I. Smith, B. Evans, J. Millar, 1983, British Journal of Cancer.

Neoadjuvant chemotherapy for breast cancer

I. Smith, F. Sapunar, 2000, Annals of medicine.

Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging.

D O Cosgrove, D. Cosgrove, I. Smith, 1994, Radiology.

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.

T. Eisen, I. Smith, P. Ross, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations

M. Dowsett, I. Smith, E. López-Knowles, 2018, British Journal of Cancer.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

M. Dowsett, S. Johnston, I. Smith, 2014, Clinical Cancer Research.

Trastuzumab and other novel therapies in breast cancer

Robin L. Jones, I. Smith, 2006 .

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2016, European journal of cancer.

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

M. Dowsett, R. Gelber, J. Baselga, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013 .

Trastuzumab for Early Breast Cancer: Hope or Hype?

I. Smith, 2006, Breast Care.

Breast radiotherapy after lumpectomy--no longer always necessary.

I. Smith, G. Ross, 2004, The New England journal of medicine.

Medical management of non-small cell lung cancer.

I. Smith, 1995, European journal of cancer.

The follow-up of women at high risk for breast cancer relapse.

I. Smith, S. Banerjee, 2009, Breast.

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.

T. Hickish, I. Smith, G. Middleton, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide.

I. Smith, A. Jones, S. Ashley, 1991, European journal of cancer.

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.

M. Gore, J. Yarnold, I. Smith, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging.

I. Smith, M. Vincent, S. Ashley, 1987, European journal of cancer & clinical oncology.

Comparison of different endocrine therapies in management of bone metastases from breast carcinoma.

I. Smith, V. Macaulay, 1985, Journal of the Royal Society of Medicine.

The pharmacokinetics of oral lonidamine in breast and lung cancer patients.

I. Smith, D. Newell, J. Hardy, 1991, Seminars in oncology.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

E. Winer, G. Hortobagyi, Baljit Singh, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).

R. Laing, T. Hickish, S. Ebbs, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.

R. Laing, A. Howell, T. Hickish, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer

M. Dowsett, Z. Ghazoui, I. Smith, 2008, Clinical Cancer Research.

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer

M. Dowsett, L. Assersohn, I. Smith, 2017, Breast Cancer Research and Treatment.

Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.

S. Johnston, I. Smith, N. Turner, 2017, Breast.

Lymphoma presenting as "Idiopathic" juvenile osteoporosis.

I. Smith, J. Child, 1975, British medical journal.

Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer

M. Dowsett, G. Viale, I. Smith, 2014, Breast Cancer Research and Treatment.

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

T. Powles, M. Dowsett, R. Coombes, 1996, British Journal of Cancer.

Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.

I. Smith, R. Stuart-Harris, H. Rogers, 1985, British journal of cancer.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer

M. Dowsett, I. Smith, A. Sheri, 2017, Breast Cancer Research and Treatment.

Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience.

I. Smith, 1992, Seminars in oncology.

Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?

S. Johnston, I. Smith, S. Ashley, 2010, Breast.

Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors.

T. Hickish, I. Smith, G. Middleton, 1998, British Journal of Cancer.

Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience.

S. Johnston, I. Smith, E. Kipps, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer

M. Dowsett, M. Cheang, M. Clemons, 2021, Breast Cancer Research and Treatment.

Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response

M. Dowsett, Z. Ghazoui, I. Smith, 2010 .

Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study

M. Dowsett, L. Zabaglo, I. Smith, 2015, Journal of Clinical Pathology.

Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.

T. Powles, D. Easton, R. Coombes, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locally Advanced Breast Cancer

I. Smith, A. Kuciejewska, 2009 .

Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.

P. Ellis, S. Ebbs, M. Baum, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is S urgery N ecessary A fter C omplete C linical R emission Following N eoadjuvant C hemotherapy f or E arly B reast C ancer

S. Ebbs, I. Smith, G. Gui, 2003 .

Primary chemotherapy in breast cancer.

I. Smith, M. Al-Moundhri, 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Primary/Neoadjuvant Chemotherapy for Early Breast Cancer

I. Smith, 1997 .

Primary chemotherapy for early breast cancer.

P. Ellis, I. Smith, 1996, Cancer treatment reviews.

Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.

T. Powles, M. Dowsett, R. Coombes, 1982, Cancer Research.

Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015)

M. Dowsett, J. Robertson, E. Mallon, 2018 .

Association between breast cancer subtypes and response to neoadjuvant anastrozole

C. Perou, M. Dowsett, J. Parker, 2011, Steroids.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

I. Ellis, M. Dowsett, P. Ellis, 2009 .

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Agranulocytosis associated withaminoglutethimide: Pharmacological andmarrow studies

M. Dowsett, A. Barrett, I. Smith, 1986 .

Pivotal trials of letrozole: a new aromatase inhibitor.

I. Smith, 1998, Oncology.

Response to third-line endocrine treatment for advanced breast cancer.

I. Smith, T. Iveson, T. Iveson, 1993, European journal of cancer.

Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

R. Gelber, M. Piccart, J. Baselga, 2015, Breast Cancer Research and Treatment.

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

M. Namer, J. Bonneterre, J. Zalcberg, 1996, British Journal of Cancer.

Adjuvant tamoxifen for early breast cancer.

I. Smith, 1988, British Journal of Cancer.

Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone

M. Gore, I. Smith, J. Mcvie, 2004, Cancer Chemotherapy and Pharmacology.

Pattern of care in locally advanced breast cancer: focus on local therapy.

M. Piccart, J. Bogaerts, P. Therasse, 2011, Breast.

A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2013 .

Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

E. Winer, J. Cuzick, J. Bergh, 2017 .

Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer.

I. Smith, J. Anderson, J. Hunt, 1981, British medical journal.

SEX HORMONE BINDING GLOBULIN LEVELS AND PROGNOSIS IN EARLY BREAST CANCER

T. Powles, M. Dowsett, A. Harris, 1981, The Lancet.

Carcinoid tumour presenting as an orbital metastasis.

I. Smith, J. Gazet, A. Harris, 1981, Clinical oncology.

Tamoxifen-induced tumour regression associated with dermatomyositis.

A. Harris, M. Snaith, I. Smith, 1982, British medical journal.

Scalp hypothermia to prevent adriamycin-induced hair loss.

I. Smith, J. Anderson, J. Hunt, 1982, Cancer nursing.

A randomised trial of cyclophosphamide pretreatment ('priming') before short-duration chemotherapy for small cell lung carcinoma.

I. Smith, J. Millar, S. Harland, 1985, European Journal of Cancer and Clinical Oncology.

Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma.

I. Smith, A. Sappino, P. Bondy, 1981, European journal of cancer & clinical oncology.

Priming reduces the bone marrow toxicity of carboplatin.

M. Gore, J. Sloane, I. Smith, 1987, European journal of cancer & clinical oncology.

Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide.

I. Smith, B. Evans, R. Clutterbuck, 1983, Cancer treatment reviews.

High dose chemotherapy and autologous bone marrow rescue in the treatment of breast cancer

I. Smith, 1992 .

Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen.

P. Ellis, I. Smith, J. Treleaven, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects

I. Smith, S. Popat, 2008, Nature Clinical Practice Oncology.

Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma

A. Padhani, I. Smith, M. O'Brien, 2002, British Journal of Cancer.

Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials

I. Smith, L. Cataliotti, 2004 .

Adjuvant endocrine therapy for early breast cancer.

I. Smith, C. Andreetta, 2007, Cancer letters.

Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

I. Smith, S. Popat, 2005, Journal of the National Cancer Institute.

Management of small HER2-positive breast cancers.

I. Smith, Susana Banerjee, S. Banerjee, 2010, The Lancet. Oncology.

The Growth of Colonies of Human Bone Marrow and Tumour Cells in Soft Agar in Diffusion Chambers

I. Smith, M. Gordon, P. Selby, 1980 .

Cell filtration‐laser scanning cytometry for the characterisation of circulating breast cancer cells

Mitch Dowsett, Lila Zabaglo, M. Dowsett, 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?

I. Smith, G. Schiavon, B. Yeo, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

The response of human tumour cells to radiation and cytotoxic drugs

I. Smith, 1978 .

CARBOPLATIN CHEMOTHERAPY FOR MALIGNANT PARAGANGLIOMA

I. Smith, F. Cairnduff, 1986, The Lancet.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

M. Dowsett, J. Reis-Filho, J. Salter, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial

U. Pastorino, I. Smith, P. Goldstraw, 1999, British Journal of Cancer.

Inefficacy of calcipotriol In skin metastases from breast cancer

K. Maclennan, D. Talbot, I. Smith, 1993, The Lancet.

[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo.

I. Smith, V. Macaulay, J. Millar, 1993, European journal of cancer.

Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer

I. Smith, M. Stuart, Lisa Renee Bailey Iacona, 2009 .

Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer

M. Dowsett, M. Clemons, I. Smith, 2019, npj Breast Cancer.

Mechanisms of hormone response: a role for apoptosis

M. Dowsett, S. Johnston, I. Smith, 1995 .

Screening for lung cancer: time to think positive

I. Smith, 1999, The Lancet.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis

M. Dowsett, R. Gelber, M. Piccart, 2016 .

Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer.

T. Powles, R. Coombes, I. Smith, 1985, British medical journal.

The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.

I. Smith, M. Arnedos, 2007, Breast.

Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial.

M. Dowsett, I. Smith, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study.

P. Ellis, S. Johnston, I. Smith, 2000, Breast.

Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders.

J. Olson, C. Perou, M. Ellis, 2009 .

Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

R. Gelber, J. Baselga, Bing-he Xu, 2017 .

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer

M. Dowsett, E. Mallon, I. Smith, 2018, JNCI cancer spectrum.

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

I. Smith, E. Moskovic, M. Seymour, 1997, British Journal of Cancer.

Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery

M. Dowsett, Hsin-Ta Wu, H. Sethi, 2022, Cancer Research.

PROPHYLACTIC CRANIAL IRRADIATION IN SMALL-CELL LUNG CANCER

J. Yarnold, I. Smith, J. Yarnold, 1985, The Lancet.

471 Capecitabine in older patients ⩾70 yrs with locally advanced or metastatic breast cancer

I. Smith, G. Walsh, S. Ashley, 2010 .

Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience

T. Powles, M. Dowsett, L. Assersohn, 1999 .

Chylous ascites in Kaposi's sarcoma: a case report

D. Talbot, I. Smith, K. Fife, 1992, The British journal of dermatology.

AMINOGLUTETHIMIDE IN BREAST CANCER

T. Powles, A. Forrest, I. Smith, 1978, The Lancet.

A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer.

H. Mackay, I. Smith, N. Thatcher, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

HIGH-DOSE CARBOPLATIN (JM8) IN PATIENTS WITH LUNG-CANCER - A PHASE-I STUDY

M. Gore, I. Smith, A. Calvert, 1986 .

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015 .

How should cancer presenting as a malignant pleural effusion be managed?

H. Bonnefoi, I. Smith, 1996, British Journal of Cancer.

SYMPTOMATIC HYPOCALCAEMIA AFTER TREATMENT WITH HIGH-DOSE AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE

I. Smith, D. Jodrell, T. Iveson, 1987, The Lancet.

Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach

M. Dowsett, S. Johnston, I. Smith, 2021, Clinical Research (Excluding Clinical Trials).

Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer

M. Dowsett, M. Clemons, I. Smith, 2019, npj Breast Cancer.

The development and clinical use of trastuzumab (Herceptin).

I. Smith, M. Harries, I. Smith, 2002, Endocrine-related cancer.

Breast cancer and pregnancy.

P. Ellis, I. Smith, A. Ring, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

43PDevelopment and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: Implementation for clinical routine use

I. Smith, G. Schiavon, N. Turner, 2015 .

Plasma calcitonin in small cell lung cancer: prognostic significance.

I. Smith, A. Sappino, S. Carter, 1983, British Journal of Cancer.

Patient benefits from new treatment options and schedules for breast cancer.

I. Smith, 1997, Seminars in oncology.

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

A. Makris, D. Miles, S. Johnston, 2006, Cancer Chemotherapy and Pharmacology.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012 .

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

M. Dowsett, S. Johnston, I. Smith, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Trastuzumab after adjuvant chemotherapy in older patients – Authors' reply

R. Gelber, M. Piccart-Gebhart, M. Procter, 2007, The Lancet.

Trastuzumab after adjuvant chemotherapy in older patients - Reply

R. Gelber, M. Piccart-Gebhart, M. Procter, 2007 .

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

M. Dowsett, M. Cheang, J. Reis-Filho, 2015, Science Translational Medicine.

Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

C. Perou, M. Ellis, M. Dowsett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

A. Ashworth, C. Perou, N. Rahman, 2018, Nature Medicine.

75 Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma

I. Smith, G. Middleton, M. O'Brien, 1997 .

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

A. Giobbie-Hurder, J. Forbes, R. Gelber, 2009, The New England journal of medicine.

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

A. Ashworth, M. Dowsett, J. Reis-Filho, 2010, Clinical Cancer Research.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Presurgical progesterone in early breast cancer: so much for so little?

M. Dowsett, I. Smith, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pattern of care in locally advanced breast cancer: focus on local therapy.

M. Piccart, J. Bogaerts, P. Therasse, 2011, Breast.

Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?

I. Smith, A. Leary, 2006, Nature Clinical Practice Oncology.

Controversies in the medical management of breast cancer.

I. Smith, 1985, Postgraduate medical journal.

Adjuvant chemotherapy for early breast cancer

I. Smith, 1983, British medical journal.

Adjuvant chemotherapy for early breast cancer.

I. Smith, 1983, British medical journal.

Endocrine therapy for advanced/metastatic breast cancer.

I. Smith, G. Schiavon, 2013, Hematology/oncology clinics of North America.

Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.

A. Giobbie-Hurder, E. Winer, J. Forbes, 2013 .

Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial

C. Normand, I. Smith, J. Haviland, 2002, BMJ : British Medical Journal.

The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer

M. Dowsett, Z. Ghazoui, I. Smith, 2008, Clinical Cancer Research.

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer.

M. Dowsett, P. Ellis, I. Smith, 1998, Journal of clinical pathology.

Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer.

M. Dowsett, I. Smith, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.

D. Tait, I. Smith, G. Schiavon, 2013, Clinical breast cancer.

New treatments for advanced cancer: an approach to prioritization

I. Smith, S. Masters, I. Smith, 2000, British Journal of Cancer.

ADRIAMYCIN IN ACUTE LEUKÆMIA

I. Smith, T. Mcelwain, 1974 .

Management of Hodgkin's disease in childhood.

I. Smith, T. Mcelwain, 1977, Archives of disease in childhood.

The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer

T. Powles, R. Coombes, J. Gibb, 2004, Cancer Chemotherapy and Pharmacology.

Vindesine in the treatment of breast cancer

T. Powles, I. Smith, 2004, Cancer Chemotherapy and Pharmacology.

The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy.

I. Smith, A. Kirby, G. Walsh, 2011, European journal of cancer.

Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up

M. Dowsett, R. Gelber, M. Piccart, 2012 .

A study of factors determining outcome of patients receiving third line chemotherapy for metastatic breast cancer: The Royal Marsden Hospital experience.

S. Johnston, U. Banerji, I. Smith, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

M. Dowsett, J. Reis-Filho, J. Salter, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations

M. Dowsett, I. Smith, E. López-Knowles, 2018, British Journal of Cancer.

Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.

P. Ellis, I. Smith, A. Ring, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience.

S. Johnston, I. Smith, N. Turner, 2017, Breast.

Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience

I. Smith, A. Ring, N. Battisti, 2019, Breast Cancer Research and Treatment.

Primary medical chemotherapy with continuous infusional 5-fu (F), epirubicin (E) and cisplatin (P) for large operable breast cancer: a very active new regimen

S. Ebbs, M. Baum, I. Smith, 1993 .